China News Service, Beijing, February 19 (Ren Jing) On the 19th, the State Council's joint prevention and control mechanism held a press conference.
It was introduced at the meeting that the local epidemic situation in my country has generally remained stable, the epidemic in Baise in Guangxi is in the final stage of clearing, the epidemic in Suzhou, Jiangsu is still in the stage of rapid development, and the epidemic in Hohhot, Inner Mongolia, has a high risk of community transmission and spillover.
Conference site.
Photo by Ren Jing
The trend of the epidemic in Huludao is positive, and there is a risk of spillover from the epidemic in Hohhot
According to Wu Liangyou, deputy director of the National Health Commission's Bureau of Disease Control and Prevention, the local epidemic situation in my country has generally remained stable.
Among them, the Baise epidemic in Guangxi is in the final stage of clearing.
The recent new cases in Huludao, Liaoning Province were mainly found through centralized isolation and screening. The epidemic trend is improving, and the risk of social transmission is basically under control.
At present, the epidemic situation in Heihe, Heilongjiang is mainly concentrated in Heihe City, and there are multiple chains of transmission. Further epidemiological tracing and case investigation are being carried out in an orderly manner.
In Guangdong, Shenzhen, Zhuhai, and Dongguan have recently experienced clustered epidemics caused by overseas imports. The related epidemic in Shenzhen Omicron has been basically controlled. The epidemic in Dongguan and Zhuhai is strengthening the work of tracing the source of the epidemic, and making every effort to prevent the spread of the epidemic.
Epidemic outbreaks have occurred in Wenshan, Honghe, and Ruili in Yunnan, and the source of infection is still unclear. The local area is making every effort to speed up nucleic acid screening in key areas, speed up the investigation of risk sources, and prevent the epidemic from spreading from border areas to inland areas.
The genetic sequencing result of the epidemic in Suzhou, Jiangsu is a variant of Omicron, which is a local epidemic caused by a new overseas import source, and is still in the stage of rapid development.
The local area is speeding up the work of tracing the source of the epidemic, expanding nucleic acid screening in risk areas, and strengthening the inspection of personnel in key places to prevent the further spread of the epidemic.
The gene sequencing result of the epidemic in Hohhot, Inner Mongolia, is a delta variant, which is a local epidemic caused by a new overseas import source, which has spread to Baotou City.
At present, the epidemic is at an early stage, the number of cases is growing rapidly, and there are clusters of epidemics in places with dense crowds such as work units and wedding banquets. There is a high risk of community transmission and spillover. It is necessary to investigate the source of risks and key places as soon as possible to find out the scope of the epidemic. .
At present, the working group dispatched by the comprehensive group of the Joint Prevention and Control Mechanism of the State Council has jointly dealt with the clustered epidemics in Liaoning, Inner Mongolia, Guangdong and other provinces and regions.
my country has begun deploying sequential booster immunizations
At the meeting, Wu Liangyou, deputy director of the National Health Commission's Bureau of Disease Control and Prevention, said that recently, with the approval of the State Council's joint prevention and control mechanism, the National Health Commission has begun to deploy sequential booster immunizations.
Wu Liangyou said that research data show that both homologous booster immunization and sequential booster immunization can further improve the immune effect.
Previously, all target groups over the age of 18 who have been vaccinated with Sinopharm Zhongsheng Beijing Company, Wuhan Company, Beijing Kexing Company's inactivated vaccine, and Tianjin CanSino Company's adenovirus vector vaccine for 6 months can receive one dose of homology. Boost immunity.
After the implementation of the sequential booster immunization strategy, the target groups who have completed the whole process of inoculation with the above three inactivated vaccines can choose the recombinant protein vaccine of Zhifeilong Coma or the adenovirus vector vaccine of CanSino for sequential booster immunization.
For the target population, one of homologous booster immunization and sequential booster immunization can be selected.
In addition, the State Council's joint prevention and control mechanism has also approved the homologous booster immunization of the new coronavirus inactivated vaccine from Shenzhen Kangtai Company and the Institute of Biology, Academy of Medical Sciences.
Whether it is homologous boosting or sequential boosting, it is implemented in people over the age of 18 who have completed the full course of vaccination for 6 months.
According to Wang Huaqing, chief expert of the immunization program of the Chinese Center for Disease Control and Prevention, sequential immunization is the vaccination of vaccines of different technical routes at a certain interval of vaccination.
That is to say, the current vaccination is also completed 4 doses, the first two doses are vaccinated with inactivated trivalent polio vaccine, and the last two doses are vaccinated with bivalent live attenuated vaccine.
Wang Huaqing also reminded that there are some special precautions for sequential vaccination: the inoculation target should be people over 18 years old; complete 2 doses of inactivated vaccine, and these 2 doses were vaccinated by Sinopharm Zhongsheng Beijing Company and Beijing Kexing Company , Sinopharm Zhongsheng Wuhan Company's new coronavirus inactivated vaccine; 2 doses of vaccination must be completed throughout the whole process, and the vaccination interval cannot be shorter than 6 months; no booster immunization has been performed, that is, the third injection has not been given.
(over)